Fibrosis: How collagen becomes ‘stiff’
Oxidative stress following a lung injury can alter the structure of collagen, causing it to stiffen and trigger the formation of a fibrotic scar that further hardens the tissue.
- Department of Medicine, University of Pennsylvania, United States
When our bodies heal following an injury, fibroblasts and other cells deposit components of the extracellular matrix, such as collagen, that form a ‘scar’ over the damaged area. This process, known as fibrosis, leads to a build-up of stiff fibrotic tissue that interferes with the activity of the underlying organ.
In healthy organs, fibroblasts lay down just enough collagen to maintain the integrity of the tissue (D’Urso and Kurniawan, 2020). However, if the tissue begins to stiffen, these cells produce more collagen, disrupting this equilibrium (Tschumperlin et al., 2018). This increases the rigidity of the organ, triggering the fibroblasts to release even more collagen. While this explains how fibrosis progresses, it is less clear how the cycle starts.
Previous studies showed that fibrosis is initiated by changes in the mechanical properties of collagen that arise from modifications to its structure (Jones et al., 2018; Georges et al., 2007). The experiments found that, after a tissue injury, a family of enzymes called lysyl oxidases (or LOXs for short) increase the bonds between individual collagen fibers in the organ. This modified structure makes the tissue stiffer, driving the fibrotic process. Now, in eLife, Mark Jones from the University of Southampton and co-workers – including Christopher Brereton and Liudi Yao as joint first authors – report on the pathway that leads to this altered collagen architecture in patients with pulmonary fibrosis (Brereton et al., 2022).
First, the team (who are based at various institutes in the United Kingdom, the United States, Austria, Italy and Ireland) studied lung tissue from individuals with idiopathic pulmonary fibrosis, a disease of unknown cause in which patient’s lungs are severely scarred (Richeldi et al., 2017). They found that the genes coding for two enzymes that sequentially modify collagen (Yamauchi and Sricholpech, 2012) – lysyl hydroxylase PLOD2 and LOXL2 – were highly expressed in the same lung cells at the same time. The gene for the most commonly found type of collagen in fibrosis (called type I) was also activated in the lung tissue, but its pattern of expression did not correlate with the genes for PLOD2 or LOXL2. This suggests that it is regulated independently from these two enzymes.
Next, Brereton, Yao et al. extracted fibroblasts from patients with idiopathic pulmonary fibrosis and cultured them in the laboratory for six weeks, treating the cells with several growth factors associated with fibrosis. The experiments showed that a family of proteins called Hypoxia Inducible Factors (HIFs), which regulate the body’s response to varying oxygen levels, activated the genes for PLOD2 and LOXL2. This increased the number of cross-links between the collagen fibers and made the fibers stiffer. Imaging the collagen produced by these cells with an electron microscope revealed that the fibers had a smaller diameter, as had previously been observed in patients with idiopathic pulmonary fibrosis (Jones et al., 2018). This suggests that HIFs regulate tissue mechanics not by increasing the amount of collagen, but by altering collagen’s structure.
HIF is negatively regulated by another protein called FIH (short for Factor Inhibiting HIF), which is inactivated by the unstable byproducts of oxygen metabolism, also known as oxidative stress (Lando et al., 2002). Loss of FIH causes cells to enter ‘pseudohypoxia’, a state in which cells behave as if oxygen levels are low despite being in normal conditions (Masson et al., 2012). Brereton, Yao et al. found that reducing FIH – both in cells cultured in the laboratory as well as in lung tissue from patients with idiopathic pulmonary fibrosis – led to higher levels of HIF, which increased the activity of PLOD2 and LOX2, causing changes to collagen’s architecture and fibrosis.
These findings suggest that the pseudohypoxia state induced by oxidative stress is central to the pathology of idiopathic pulmonary fibrosis, and may help to explain how the fibrosis cycle starts (Figure 1): injuring or damaging the lung leads to a rise in oxidative stress, which dampens the level of FIH. This allows HIF to activate the genes for the enzymes PLOD2 and LOXL2, which then sequentially alter the structure of collagen. These changes increase the stiffness of the tissue, initiating the fibrosis cycle.
Figure 1
The pathway to fibrosis.
When cells in the lung become injured or damaged (left), the resulting increase in oxidative stress leads to a decrease in the expression of the genes that code for a protein called FIH (purple triangle). This results in a pseudohypoxia state which increases the activity of the protein HIF (pink circle), allowing it to upregulate the expression of the genes that code for two enzymes: PLOD2 and LOXL2. These enzymes act in sequence to increase and strengthen the bonds, or ‘cross-links’, between fibers of collagen. The altered structure stiffens the tissue, triggering cells in the lung to deposit more collagen and start the process of fibrosis. HIF: Hypoxia Inducible Factor; FIH: Factor Inhibiting HIF.
Image credit: Iris de Jong (CC BY 4.0).
This work provides new insights in to how fibrosis is triggered. Particularly intriguing is the suggestion that intervening at the level FIH or HIF may be better at treating idiopathic pulmonary fibrosis than targeting the machinery that synthesizes collagen, which is currently considered to be the most effective approach. Further work is needed to fully understand how the architecture of collagen becomes dysregulated and to test how substances that block this newly discovered pathway impact fibrosis.
References
-
Mechanical and physical regulation of fibroblast-myofibroblast transition: from cellular mechanoresponse to tissue pathologyFrontiers in Bioengineering and Biotechnology 8:609653.https://doi.org/10.3389/fbioe.2020.609653
-
Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosisAmerican Journal of Physiology. Gastrointestinal and Liver Physiology 293:G1147–G1154.https://doi.org/10.1152/ajpgi.00032.2007
-
Mechanosensing and fibrosisThe Journal of Clinical Investigation 128:74–84.https://doi.org/10.1172/JCI93561
-
Lysine post-translational modifications of collagenEssays in Biochemistry 52:113–133.https://doi.org/10.1042/bse0520113
Article and author information
Author details
Publication history
- Version of Record published: February 21, 2022 (version 1)
Copyright
© 2022, Wells
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 4,879
- Page views
-
- 312
- Downloads
-
- 3
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Fibrosis: How collagen becomes ‘stiff’
eLife 11:e77041.
https://doi.org/10.7554/eLife.77041
Further reading
-
- Biochemistry and Chemical Biology
- Cell Biology
Nitric oxide (NO), as a gaseous therapeutic agent, shows great potential for the treatment of many kinds of diseases. Although various NO delivery systems have emerged, the immunogenicity and long-term toxicity of artificial carriers hinder the potential clinical translation of these gas therapeutics. Mesenchymal stem cells (MSCs), with the capacities of self-renewal, differentiation, and low immunogenicity, have been used as living carriers. However, MSCs as gaseous signaling molecule (GSM) carriers have not been reported. In this study, human MSCs were genetically modified to produce mutant β-galactosidase (β-GALH363A). Furthermore, a new NO prodrug, 6-methyl-galactose-benzyl-oxy NONOate (MGP), was designed. MGP can enter cells and selectively trigger NO release from genetically engineered MSCs (eMSCs) in the presence of β-GALH363A. Moreover, our results revealed that eMSCs can release NO when MGP is systemically administered in a mouse model of acute kidney injury (AKI), which can achieve NO release in a precise spatiotemporal manner and augment the therapeutic efficiency of MSCs. This eMSC and NO prodrug system provides a unique and tunable platform for GSM delivery and holds promise for regenerative therapy by enhancing the therapeutic efficiency of stem cells.
-
- Biochemistry and Chemical Biology
- Cell Biology
The ATPase p97 (also known as VCP, Cdc48) has crucial functions in a variety of important cellular processes such as protein quality control, organellar homeostasis, and DNA damage repair, and its de-regulation is linked to neuromuscular diseases and cancer. p97 is tightly controlled by numerous regulatory cofactors, but the full range and function of the p97–cofactor network is unknown. Here, we identify the hitherto uncharacterized FAM104 proteins as a conserved family of p97 interactors. The two human family members VCP nuclear cofactor family member 1 and 2 (VCF1/2) bind p97 directly via a novel, alpha-helical motif and associate with p97-UFD1-NPL4 and p97-UBXN2B complexes in cells. VCF1/2 localize to the nucleus and promote the nuclear import of p97. Loss of VCF1/2 results in reduced nuclear p97 levels, slow growth, and hypersensitivity to chemical inhibition of p97 in the absence and presence of DNA damage, suggesting that FAM104 proteins are critical regulators of nuclear p97 functions.
